Glenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalates competition in a rapidly growing market. The Indian patent for semaglutide expires soon, allowing multiple local drugmakers to enter. Glenmark plans a comprehensive patient support program to differentiate its offering. This will benefit millions of Indians suffering from diabetes and obesity.